
The pandemic has had a widespread impact across the healthcare industry and the world, however, a recent global survey from …

Pfizer has announced that it will begin large-scale testing of its COVID-19 vaccine after selecting a lower dose of the …

Ipsen and Exelixis have announced detailed results from the Phase III COSMIC-311 pivotal trial of Cabozantinib in patients with previously …

Biogen’s controversial new drug, aducanumab, has been accepted by the FDA, making it the first Alzheimer’s drug to be approved …

The MHRA has announced its approval for AbbVie’s venetoclax, in combination with a hypomethylating agent, for the treatment of newly …

Merk (MSD) has announced positive data from its Phase III Clear/Keynote-581 trial on Keytruda (pembrolizumab) plus Lenvima (lenvatinib), and Lenvima …

A newly published Final Appraisal Determination by NICE has recommended Astellas’ Xtandi (enzalutamide) plus androgen deprivation therapy (ADT), as an …

Astronomers from Durham University have joined forces with cancer researchers to advance the diagnosis and treatment of cancer of unknown …

With 21 June fast approaching, and the Delta variant rising in the UK, here’s the latest vaccine update. Firstly, the …

AstraZeneca has launched a court case against Glaxo Smith Kline (GSK), in a claim that could reach hundreds of millions …

Avacta has announced that the MHRA has confirmed registration of the AffiDX SARS-CoV-2 antigen lateral flow test, which allows the …

The FDA has updated the Emergency Use Authorisation (EUA) for Regeneron Pharmaceuticals’ COVID-19 antibody cocktail, REGEN-COV, halving the dose from …

Among our ten most-read stories this week: NICE rejects risdiplam for treating spinal muscular atrophy; The EU wants to Fine …

Novartis’s 177Lu-PSMA-617 has shown to significantly improve overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer …

Bristol Myers Squibb (BMS) has announced results from the Phase III CheckMate -648 trial in which nivolumab plus chemotherapy and …

Results from OlympiA’s Phase III trial has shown that its Olaparib (Lynparza) in the adjuvant treatment of patients with germline …

Johnson & Johnson’s interleukin-23 (IL-23) Tremfya (guselkumab) has shown positive results in Phase IIIb trials, in post-tumour necrosis factor (TNF) …

China’s Sinovac COVID-19 vaccination has received an emergency use listing (EUL) from the WHO. This decision means the jab can …

Vaxxas, an Australian clinical-stage biotechnology company, has announced positive results from pre-clinical trials into its novel high-density microarray patch (HD-MAP) …

vasopharm GmbH has announced that its NOSTRA III traumatic brain injury (TBI) Phase III clinical trial of ronopterin did not …